Shares of major vaccine companies fell Thursday after President-elect Donald Trump nominated Robert F. Kennedy Jr., a ...

A world-first vaccine for the virus is to start trail in Scotland in the next few weeks, with biotechnology company Moderna ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter. He will remain chief executive officer of the biotech company.

Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...

World Pasta Day is celebrated every year on October 25th. Read on to learn about the origin of pasta. Check out some yummy Indian-style pasta recipes. Pasta can be considered an Italian counterpart of ...

Barclays lowered the firm’s price target on Moderna (MRNA) to $111 from $125 and keeps an Overweight rating on the shares. The company’s Q3 SpikeVax revenue beat estimates and guidance was ...

World Pasta Day celebrates Italian pasta in its many shapes and forms. The pasta of Emilia Romagna reflects the region’s rich culinary history and traditions. Italy, the world leader in pasta ...

The stock price of Moderna (NASDAQ:MRNA) has seen a sharp 48% fall this year. From its lows of around $50, it is expected to see a rebound after posting a solid Q3 beat. The company reported ...

“Years later, this breakthrough would be the key to delivering Moderna’s mRNA vaccine into the targeted cells that would trigger an immune response in the body.” – Northwestern complaint ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus, or RSV, in adults 60 years and older, making it the country's first authorized mRNA-based ...